Clascoterone: First Approval

October 2020 in “ Drugs ”

Sohita Dhillon

We don't know much about this study yet.

We're maintaining the world's largest resposity of hair loss research. You can help out the community by sending a PDF of this study here . Not sure how to get a study's PDF? You can email the authors of the study.

View this study on link.springer.com →

Discuss this study in the Community →

Research cited in this study

3 / 3 results

research Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris

7 citations , December 2019 in “American Journal of Clinical Dermatology”

Topical therapies show promise for hair loss and acne treatment with minimal side effects.

research Cortexolone 17α-Propionate (Clascoterone) Is an Androgen Receptor Antagonist in Dermal Papilla Cells In Vitro

4 citations , February 2019 in “PubMed”

Clascoterone may be an effective topical treatment for hair loss.

research Biological Profile of Cortexolone 17a-Propionate (CB-03-01), a New Topical and Peripherally Selective Androgen Antagonist

5 citations , December 2011 in “Drug Research”

CB-03-01 is a promising skin cream for treating hormone-related skin problems without causing harmful body-wide effects.

Related Research

1 / 1 results

research C-MYC-Induced Sebaceous Gland Differentiation Is Controlled by an Androgen Receptor/p53 Axis

60 citations , February 2013 in “Cell reports”

The balance between androgen receptor and p53 is crucial for sebaceous gland differentiation.